<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is causally linked with endemic Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> whose homogeneous cell surface phenotype suggests derivation from a particular subset of activated germinal centre B cells in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>Endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> also shows an unusual form of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> with down-regulation of certain of the virus latent proteins which are constitutively expressed when EBV infects and transforms <z:mpath ids='MPATH_458'>normal</z:mpath> resting B cells in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>Here we question whether this virus:cell interaction is unique to malignant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells or whether it might be reproduced by in vitro <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of those particular germinal centre cells displaying the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like phenotype </plain></SENT>
<SENT sid="3" pm="."><plain>Firstly, we show by biochemical means that a subset of <z:mpath ids='MPATH_458'>normal</z:mpath> tonsillar B cells does indeed express the globotriaosylceramide <z:chebi fb="0" ids="33563">glycolipid</z:chebi> BLA and the common <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> antigen CALLA, 2 important markers of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> phenotype </plain></SENT>
<SENT sid="4" pm="."><plain>Secondly, using 2-colour immunofluorescence labelling with anti-BLA and anti-CALLA monoclonal antibodies (MAbs), 4 subsets of low buoyant density tonsillar B cells (BLA+ CALLA+, BLA+ CALLA-, BLA- CALLA+, BLA- CALLA-) have been separated by means of a FACS and tested for their susceptibility to EBV-induced growth transformation in a limiting dilution assay </plain></SENT>
<SENT sid="5" pm="."><plain>The BLA+ CALLA+ (i.e., <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like) subset contained the highest proportion of cells already actively in cycle in vivo and gave the lowest yield of transformants, perhaps reflecting the greater efficiency with which EBV transforms resting target cells </plain></SENT>
<SENT sid="6" pm="."><plain>Of the cell lines established from the BLA+ CALLA+ population, a significant number retained BLA expression but CALLA was always lost </plain></SENT>
<SENT sid="7" pm="."><plain>In 2 further respects, these lines resembled conventional in vitro transformants rather than lines of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> type; thus the cells expressed cellular "activation" antigens (CD23, CD39, CD30, Ki-24) characteristic of the lymphoblastoid phenotype and contained the full spectrum of EBV latent proteins </plain></SENT>
</text></document>